Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.

Thrombosis and haemostasis - 30 Aug 2017

Janion-Sadowska Agnieszka, Natorska Joanna, Siudut Jakub, Ząbczyk Michal, Stanisz Andrzej, Undas Anetta

Abstract excerpt

We sought to investigate whether the G20210A prothrombin mutation modifies plasma fibrin clot properties in patients after venous thromboembolism (VTE) and how rivaroxaban treatment affects these alterations. We studied 34 prothrombin mutation heterozygous carriers and sex- and age-matched 34 non-carriers, all at least three months since the first VTE episode, before and during treatment with rivaroxaban. Clot...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Blood Coagulation Tests

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibrin

Share to Fibrinolysis

Share to Prothrombin

Share to Pulmonary Embolism

Share to Venous Thromboembolism

Share to Venous Thrombosis

Source

Identifiers

PMID: 28771277
DOI: 10.1160/TH17-01-0060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.PMID 28771277Read ↗

Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype.Semantic proximity Read ↗

Clinical and laboratory management of the prothrombin G20210A mutation.Semantic proximity Read ↗

Effect of prothrombin Belgrade mutation, causing antithrombin resistance, on fibrin clot properties.Semantic proximity Read ↗

Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism.Semantic proximity Read ↗

Coagulation activation-induced fibrinolysis biomarker changes depend on thrombophilic risk factors and their clinical phenotype: an interventional <i>in vivo</i> studySemantic proximity Read ↗

Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.Semantic proximity Read ↗

Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment.Semantic proximity Read ↗

Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.Semantic proximity Read ↗

Fibrinogen β chain and FXIII polymorphisms affect fibrin clot properties in acute pulmonary embolismSemantic proximity Read ↗

The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.Semantic proximity Read ↗

Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene.Semantic proximity Read ↗

Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.